69750-01-2

Basic information

• Product Name: 2-Chloro-6-phenylnicotinic acid
• Synonyms: 2-Chloro-6-phenyl-3-pyridinecarboxylic acid;2-Chloro-6-phenylpyridine-3-carboxylic acid;3-Pyridinecarboxylic acid, 2-chloro-6-phenyl-;2-Chloro-6-phenylpyridine-3-carboxylic acid, 3-Carboxy-2-chloro-6-phenylpyridine
• CAS NO: 69750-01-2
• Molecular Formula: C₁₂H₈ClNO₂
• Molecular Weight: 233.65
• Mol File: 69750-01-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 408.4°C at 760 mmHg
• Flash Point: 200.8°C
• Appearance: /
• Density: 1.355g/cm³
• Vapor Pressure: 2.11E-07mmHg at 25°C
• Refractive Index: 1.622
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Chloro-6-phenylnicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-6-phenylnicotinic acid(69750-01-2)
• EPA Substance Registry System: 2-Chloro-6-phenylnicotinic acid(69750-01-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 69750-01-2(Hazardous Substances Data)

Usage

General Description

2-Chloro-6-phenylnicotinic acid is a chemical compound with a molecular formula of C13H9ClNO2. It is categorized under the group of nicotinic acids and derivatives, which are structured compounds with pronated or deprotonated form of nicotinic acid, or its substitute. It has a role as a bacterial metabolite. The chemical contains a phenyl ring, which is a cyclic group of atoms containing six carbon atoms attached to hydrogen, attached at the 6th position on the nicotinic acid ring and a chlorine atom at the 2nd position. 2-Chloro-6-phenylnicotinic acid is a solid substance that is usually pink in color. There is no significant industrial use of the compound known yet as most of its uses are laboratory-based for research and synthesis purposes.

InChI:InChI=1/C12H8ClNO2/c13-11-9(12(15)16)6-7-10(14-11)8-4-2-1-3-5-8/h1-7H,(H,15,16)

Upstream product

• 43083-14-3 2-chloro-3-cyano-6-phenylpyridine 
• 43083-13-2 3-cyano-2-hydroxy-6-phenylpyridine 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 98-80-6 phenylboronic acid 

Downstream Products

• 29051-44-3 6-phenylpyridine-3-carboxylic acid 
• 85815-19-6 2-Chloro-6-phenyl-N-(1H-tetrazol-5-yl)-nicotinamide 
• 181823-88-1 2-(2,4-Dimethoxy-benzylsulfanyl)-6-phenyl-nicotinic acid 
• 1026333-99-2 2-(2,4-Dimethoxy-benzylsulfanyl)-6-phenyl-nicotinoyl chloride 
• 1026530-91-5 2-(2,4-Dimethoxy-benzylsulfanyl)-6-phenyl-N-pyridin-4-yl-nicotinamide 
• 275384-67-3 2-chloro-6-phenylpyridine-3-carboxylic acid methyl ester 
• 69750-00-1 2-chloro-6-phenyl-nicotinamide 
• 92126-72-2 6-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile 
• 139326-10-6 3-Amino-6-phenyl-thieno<2,3-b>pyridin-2-carbonitril 
• 1202163-75-4 2-methoxy-6-phenylnicotinaldehyde 
• 85815-03-8 2-methoxy-6-phenylpyridine-3-carboxylic acid 

Relevant articles and documents

ENZYME INHIBITORS

The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, and, n, are as defined herein.

PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain fused triaryl amine compounds of the following formula (for convenience, collectively referred to herein as "FTA compounds"), which, inter alia, inhibit LIM kinase (LIMK) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit LIMK activity, and in the treatment of diseases and conditions that are mediated by LIMK, that are ameliorated by the inhibition of LIMK activity, etc., including proliferative conditions such as cancer (e.g., breast cancer, prostate cancer, melanoma, glioma, etc.), as well as vasodilation (including, e.g., hypertension, angina, cerebral vasospasm, and ischemia following subarachnoid hemorrhage), neurodegenerative disorders, atherosclerosis, fibrosis, and inflammatory diseases (including, e.g., Crohn's disease and chronic obstructive pulmonary disease (COPD)), and glaucoma (also known as ocular hypertension).

Studies on antiallergic agents. I. Phenyl-substituted heterocycles with a 5-tetrazolyl or N-(5-tetrazolyl)carbamoyl group

-